ZD6474 Phase IIa Dose Finding Multicentre Study

A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]

To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively

Inclusion Criteria:

• Provision of written informed consent.
• Life expectancy of 12 weeks or longer.

Exclusion Criteria:

• Pregnancy, breast feeding or female patients wishing to become pregnant.
• Treatment with a non-approved or investigational drug within 30 days before enrolment